
The Evolution of ALK+ NSCLC Care
Panelists discuss how they will explore optimizing care for patients with ALK-positive non-small cell lung cancer (ALK+ NSCLC) through treatment selection, sequencing strategies, and interpretation of emerging clinical data.
Panel Introduction
This summary is based on an AJMC Peer Exchange program titled “Advancing ALK+ NSCLC Care: Optimizing Treatment, Sequencing, and Long-Term Outcomes,” featuring the following experts:
- Ryan Haumschild, PharmD, MS, MBA, CPEL (Moderator) - vice president of Ambulatory Pharmacy at Emory Healthcare and Winship Cancer Institute of Emory University
- Elizabeth Castronovo, NP - advanced practice provider
- Martin Dietrich, MD, PhD - oncology specialist
- Mary Grizzard, MSN, FNP - family nurse practitioner
- Christine M. Lovly, MD, PhD, FASCO - oncology researcher/physician
Introduction and Treatment Landscape Evolution
- Dr Haumschild introduced the program focus on ALK+ NSCLC care optimization
- Dr Lovly posed a question regarding how the treatment landscape has evolved in recent years
- Panelists established the foundation for discussing advances in ALK-targeted therapies
Program Overview
The panelists explore strategies for optimizing care of patients with ALK-positive non–small cell lung cancer through evidence-based treatment selection, sequencing approaches, and interpretation of emerging clinical data to improve long-term outcomes.
Newsletter
Stay ahead of policy, cost, and value—subscribe to AJMC for expert insights at the intersection of clinical care and health economics.